BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22404405)

  • 1. Commentary: ursodeoxycholic acid as chemoprevention in inflammatory bowel disease and primary sclerosing cholangitis.
    Santander C; Moreno-Otero R
    Aliment Pharmacol Ther; 2012 Apr; 35(7):846; discussion 847. PubMed ID: 22404405
    [No Abstract]   [Full Text] [Related]  

  • 2. [Primary sclerosing cholangitis. To slow progression and reduce carcinoma risk].
    MMW Fortschr Med; 2006 Jun; 148(24):42-3. PubMed ID: 16850808
    [No Abstract]   [Full Text] [Related]  

  • 3. Medical therapy for primary sclerosing cholangitis.
    Wong GL; Wong VW
    Aliment Pharmacol Ther; 2011 Nov; 34(9):1135-6; discussion 1136-7. PubMed ID: 21981734
    [No Abstract]   [Full Text] [Related]  

  • 4. Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?).
    Tabibian JH; Lindor KD
    Hepatology; 2014 Sep; 60(3):785-8. PubMed ID: 24752961
    [No Abstract]   [Full Text] [Related]  

  • 5. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
    Lindström L; Boberg KM; Wikman O; Friis-Liby I; Hultcrantz R; Prytz H; Sandberg-Gertzén H; Sangfelt P; Rydning A; Folvik G; Gangsøy-Kristiansen M; Danielsson A; Bergquist A
    Aliment Pharmacol Ther; 2012 Feb; 35(4):451-7. PubMed ID: 22221173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical treatment of primary sclerosing cholangitis with ursodeoxycholic acid.
    Chapman RW
    Dig Liver Dis; 2003 May; 35(5):306-8. PubMed ID: 12846401
    [No Abstract]   [Full Text] [Related]  

  • 7. Primary sclerosing cholangitis: what is the role of ursodeoxycholic acid in therapy for PSC?
    Chapman RW
    Nat Rev Gastroenterol Hepatol; 2010 Feb; 7(2):74-5. PubMed ID: 20134486
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey.
    Okolicsanyi L; Groppo M; Floreani A; Morselli-Labate AM; Rusticali AG; Battocchia A; Colombo M; Galatola G; Gasbarrini G; Podda M; Ricci G; Rosina F; Zuin M
    Dig Liver Dis; 2003 May; 35(5):325-31. PubMed ID: 12846404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis.
    Triantos CK; Koukias NM; Nikolopoulou VN; Burroughs AK
    Aliment Pharmacol Ther; 2011 Oct; 34(8):901-10. PubMed ID: 21883323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
    Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
    Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.
    Wolf JM; Rybicki LA; Lashner BA
    Aliment Pharmacol Ther; 2005 Nov; 22(9):783-8. PubMed ID: 16225486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis.
    Stiehl A
    Ital J Gastroenterol; 1996 Apr; 28(3):178-80. PubMed ID: 8789831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ulcerative colitis and an abnormal cholangiogram.
    Nguyen DL; Lazaridis KN
    Cleve Clin J Med; 2011 May; 78(5):306-11. PubMed ID: 21536825
    [No Abstract]   [Full Text] [Related]  

  • 14. Ursodeoxycholic acid in primary sclerosing cholangitis.
    Triantos CK; Koukias N; Nikolopoulou V; Burroughs AK
    Aliment Pharmacol Ther; 2012 Mar; 35(5):622-3. PubMed ID: 22300127
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of primary sclerosing cholangitis.
    Floreani A; De Martin S
    Dig Liver Dis; 2021 Dec; 53(12):1531-1538. PubMed ID: 34011480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period.
    De Maria N; Colantoni A; Rosenbloom E; Van Thiel DH
    Hepatogastroenterology; 1996; 43(12):1472-9. PubMed ID: 8975951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprevention of colorectal cancer with ursodeoxycholic acid: cons.
    Carey EJ; Lindor KD
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S61-4. PubMed ID: 23141896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Looking Into the Crystal Ball: Predicting Non-response to Ursodeoxycholic Acid in Primary Biliary Cholangitis.
    Zimmer V; Lammert F
    EBioMedicine; 2017 Feb; 15():10-11. PubMed ID: 28007481
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
    Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL
    J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
    Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
    Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.